Skip to content

Establishment of a Prospective Clinical-biological Database

Development of a Monocentric and Prospective Clinical and Biological Database in Sarcoma

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04458792
Acronym
BCBSarcome
Enrollment
450
Registered
2020-07-07
Start date
2016-11-30
Completion date
2032-11-30
Last updated
2025-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoma

Keywords

biological specimen banks, radiotherapy

Brief summary

A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical data to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to Sarcoma

Detailed description

Liposarcomas (LPS) are soft tissue tumours of mesenchymal origin. The most common histological subtypes, represented by well differenciated Lipsarcomas (WD-LPS) and dedifferenciated (DD-LPS), are characterized by the quasi-systematic amplification of the q13-15 of chromosome 12 containing the Mdm2 gene. The systematic amplification of the Mdm2 gene is such that it is used clinically to distinguish WD/DD-LPS from other types of sarcomas. These observations raise key questions about the high selection pressure that leads to the almost systematic amplification of Mdm2 during the development of these LPS. Mdm2 is an oncoprotein whose roles in p53 tumour suppressor degradation are broadly described. However, the different inhibitors targeting this interaction were disappointing in clinical trials. Recently a team from the U1194 INSERM unit of the IRCM which collaborates in this project showed by a pan-genomics analysis, that Mdm2 is recruited to chromatin within a multiproteic complex having as target a transcriptional program involved in the metabolism and in particular in the biosynthesis of the serin. This clinical-biological basis will allow the continuation of this research project on liposarcomas and the development of new research projects on other histological types of sarcomas.

Interventions

OTHERblood sample

MDM2 project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery circulant DNA project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery radiotherapy toxicity : Blood samples collected before the radiotherapy

OTHERParaffin tissue samples

Paraffin tissue samples collected during surgery (neoplasic tissue and normal tissue

Sponsors

Institut du Cancer de Montpellier - Val d'Aurelle
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* men or women \> 18 years * Patient treated by surgery for : a primitive sarcoma and/or local relapse sarcoma and/or metastatic localisation of sarcoma * patient accepted blood sample * patient treated by radiotherapy before or after the surgery * Patient signed informed consent

Exclusion criteria

* Patient not affiliated to french Social Protection system * Patient under guardianship * Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons * Pregnancy and/or feeding * Patient take care in an Emergency Situation

Design outcomes

Primary

MeasureTime frameDescription
Establishment a clinical and biological database will provide to the scientific community a collection of blood and tissues with clinical data to improve knowledge about sarcomaUntil the study completion : 5 yearsnumber of collection of tissue samples (tumour tissue and healthy tissue) in patients operated on a sarcoma associated with clinical data.

Countries

France

Contacts

Primary ContactAurore MOUSSION
DRCI-icm105@icm.unicancer.fr4 67 61 31 02

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026